Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Loteprednol Etabonate in Cataract Surgery
NCT03531697Phase 1Completed
- Sponsor
- Sandoz
- Start
- Apr 2018
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of loteprednol etabonate in ocular inflammation (2 arms), sponsored by Sandoz. Primary endpoints: Area Under the Curve up to 1 year and Maximum Plasma Concentration up to 1 year. Started Apr 2018; status: completed.
02
Drugs
loteprednol etabonate
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT03531697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531697.